Available Clinical Trials

Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

Enhancing Relapse Prevention with rTMS: Dose-Response Parameters for Smoking Cessation
Principal Investigator: Sheffer, Christine E
(EA5162) Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR
Principal Investigator: Dy, Grace K
(B1371012) AN OPEN-LABEL PHASE 1B STUDY OF PF-04449913 (GLASDEGIB) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA
Principal Investigator: Wang, Eunice S
(ANBL1531) A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
Principal Investigator: Twist, Clare J
Evaluation of Roswell Park Cessation Services
Principal Investigator: Sheffer, Christine E
ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
Principal Investigator: Chatta, Gurkamal S
Strengthening knowledge for future generations: Cancer bio-banks in the landscapes of the Haudenosaunee
Principal Investigator: Haring, Rodney C
Evaluation of Burnout and Wellness Among Gynecologic Oncology Fellows Nationwide
Principal Investigator: Zsiros, Emese
Understanding health behaviors and perceptions of cancer in non-English speaking populations
Principal Investigator: Glaser, Kathryn M
(UTX-TGR-205) A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer
Principal Investigator: Dy, Grace K
General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial: Pragmatic Randomized Trial of Propofol vs Volatile Inhalational Anesthesia
Principal Investigator: Quinn, Timothy D
A Randomized, Open-Label Study to Assess the Pain, Toxicity and Quality of Life Effects of Adding Venlafaxine to the Pain Management Regimen for Patients Treated with Chemoradiation for Head and Neck Cancer
Principal Investigator: Singh, Anurag K
(ATLAS CO-338-085) A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Principal Investigator: Chatta, Gurkamal S
Clinical Trial and Enrollment & Oncology Pathways
Principal Investigator: McKinney-Bost, Mishellene R
OSCO-P1301 A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Principal Investigator: Wang, Eunice S
(H125001) An Open-Label Phase 1 / 2 Study of JCARH125, BCMA targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed and/or Refractory Multiple Myeloma
Principal Investigator: Lee, Kelvin
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-AXL-ADC) in patients with solid tumors.
Principal Investigator: Dy, Grace K
A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma after previous therapy with checkpoint inhibitor treatment
Principal Investigator: George, Saby
(0801) A Phase 1, Multi-center, Open-label Study of IMGN632 Administered Intravenously in Patients with Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Principal Investigator: Wang, Eunice S
Effects of package color and descriptors on tobacco product perceptions (COMET 2 1.2)
Principal Investigator: O'Connor, Richard J
A Pilot Study of Photoacoustic Imaging (PAI)
Principal Investigator: Singh, Anurag K
Identifying circadian-regulated radiosensitive markers in healthy volunteers an initial step for personalized chrono-therapy in cancer treatment
Principal Investigator: Gu, Fangyi
(NSABP B-51) A Randomized Phase III Clinical Trial Evauluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to...
Principal Investigator: Fung-Kee-Fung, Simon
RE-AIMing Nurses for Sleep Screening, Brief Intervention and Referral to Treatment (Sleep-SBIRT)
Principal Investigator: Dean, Grace E
Isolation of CD34 stem cells using the Miltenyi Biotec CliniMACS CD34 Reagent System as a humanitarian use device
Principal Investigator: Chen, George L
AALL1631 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
Principal Investigator: Twist, Clare J
(IRB17-0578) Phase I study of stereotactic body radiotherapy (SBRT) followed by nivolumab or ipilimumab with nivolumab in unresectable hepatocellular carcinoma
Principal Investigator: Iyer, Renuka V
(NRG-GI004/SWOG-S1610) Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevaczumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment...
Principal Investigator: Boland, Patrick M
Spatial Analysis of Bladder Cancer in Western New York
Principal Investigator: Guru, Khurshid
(A221504) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY OF AN ORAL, SELECTIVE PERIPHERAL OPIOID RECEPTOR ANTAGONIST IN ADVANCED NON-SMALL CELL LUNG CANCER (ADENOCARCINOMA)
Principal Investigator: Chen, Hongbin
Opioid Use in Post-operative Gynecologic Oncology Patients
Principal Investigator: Zsiros, Emese
(BGB-A317/BGB-290_Study_001) A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the anti-PD-1 Monoclonal Antibody BGB-A317 in combination with the PARP...
Principal Investigator: Fountzilas, Christos
ASTX727-02: A Phase 3, Randomized, Open-Label Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Principal Investigator: Griffiths, Elizabeth A
(ADP-0000-001) A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or...
Principal Investigator: Odunsi, Adekunle O
(ACCRU-GI-1617) MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer
Principal Investigator: Boland, Patrick M
(SGN22E-002) A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer
Principal Investigator: George, Saby
(SWOG S1616) A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent
Principal Investigator: Puzanov, Igor
A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML
Principal Investigator: Wang, Eunice S
The GYN Molecular Information Registry
Principal Investigator: Odunsi, Adekunle O
(A031501) Phase III Randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADvanced urOthelial caRcinoma (AMBASSADOR) versus observation
Principal Investigator: Levine, Ellis G
(A021502) Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch
Principal Investigator: Boland, Patrick M
NCI 10057: A Phase II Study of talimogene laherparepvec (T-VEC) Followed by talimogene laherparepvec (T-VEC) + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Principal Investigator: Puzanov, Igor
BMT CTN 1506; A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
Principal Investigator: Balderman, Sophia R
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma
Principal Investigator: Grand'Maison, Anne C
(A041501) A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
Principal Investigator: Wang, Eunice S
(ONO-7475-01) A Phase I open label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of ONO-7475 in patients with acute leukemias
Principal Investigator: Wang, Eunice S
(ALTE1631) A Randomized Web-Based Physical Activity Intervention Among Children and Adolescents with Acute Lymphoblastic Leukemia
Principal Investigator: Rokitka, Denise A
C-144-01: A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma
Principal Investigator: Ernstoff, Marc S
(APEC1621SC) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
Principal Investigator: Twist, Clare J
Electronic Cigarette Use During Pregnancy
Principal Investigator: Goniewicz, Maciej L
ALTE 15N2 LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Principal Investigator: Rokitka, Denise A
Phase II Study of Targeting CD28 in Multiple Myeloma with Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy
Principal Investigator: Lee, Kelvin
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (RGX-104-001)
Principal Investigator: Puzanov, Igor
(APEC1621) NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
Principal Investigator: Twist, Clare J
ACNS 1422 A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Principal Investigator: Twist, Clare J
AALL15P1A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
Principal Investigator: Twist, Clare J
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
Principal Investigator: Chatta, Gurkamal S
Validation of a mobile imaging system for oral cancer screening in low resource settings in India
Principal Investigator: Singh, Anurag K
(BMT CTN Protocol 1507) Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease
Principal Investigator: Balderman, Sophia R
Phase 2a Study Evaluating a Chemokine-Modulatory Regimen in Patients with Colorectal Cancer Metastatic to the Liver
Principal Investigator: Boland, Patrick M
(CA209-812) Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin...
Principal Investigator: Torka, Pallawi
A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anit-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with...
Principal Investigator: Dy, Grace K
(NRG-GY006) A Randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, or stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal...
Principal Investigator: Lele, Shashikant B
(PCYC-1141-CA) A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve...
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
A Phase Ib/II Study of Propranolol with Fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma
Principal Investigator: Gandhi, Shipra
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Principal Investigator: Wang, Eunice S
A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of FT 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
Principal Investigator: Wang, Eunice S
COG AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Principal Investigator: Twist, Clare J
RCT of Online Mindfulness-Based Stress Reduction for Metastatic Breast Cancer Patients
Principal Investigator: Hydeman, Jennifer A
The effect of extra-physiologic oxygen shock / stress (EPHOSS) on human hematopoietic stem cell viability and multi-potency
Principal Investigator: Chen, George L
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ)...
Principal Investigator: Fountzilas, Christos
AG120-C-009 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo Controlled Study of AG-120 in Combination with Azacitidine in Subjects = 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
Principal Investigator: Wang, Eunice S
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX...
Principal Investigator: Opyrchal, Mateusz
PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS
Principal Investigator: Iyer, Renuka V
A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) given with Adjuvant Poly-ICLC in Conjunction with 5-Aza-2'deoxycytidine (Decitabine) and Nivolumab in Patients with MDS or Low Blast Count AML
Principal Investigator: Griffiths, Elizabeth A
A phase 3, multi-center open-label randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors
Principal Investigator: Thompson, J E
A PHASE II TRIAL OF HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION UTILIZING MOBILIZED PERIPHERAL BLOOD STEM CELLS.
Principal Investigator: Balderman, Sophia R
Three Pilot Studies of Stereotactic Body Radiation Therapy (SBRT) and Surgery in Non-Small Cell Lung Cancer
Principal Investigator: Singh, Anurag K
Alteration of Serum Cytokines During ADT in Treatment-Naive Prostate Cancer Patients
Principal Investigator: Nastiuk, Kent L
PISCES OMS I-103: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either...
Principal Investigator: Puzanov, Igor
Pilot Study: Assess the Impact on Patient Experience With Curbell's Rego Patient Interactive Device
Principal Investigator: De Wald, Renee L
Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines Of Chemotherapy
Principal Investigator: Torka, Pallawi
CA-ALT-803-01-16, QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Principal Investigator: Guru, Khurshid
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomization Trial
Principal Investigator: Levine, Ellis G
IRONMAN: International Registry for Men with Advanced Prostate
Principal Investigator: Chatta, Gurkamal S
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Principal Investigator: George, Saby
IMCgp100-202, A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator's Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
Principal Investigator: Puzanov, Igor
A Pilot Study of Photoacoustic Imaging (PAI) in H&N Cancer Patients
Principal Investigator: Singh, Anurag K
A Phase Ib/II Trial of Interleukin-2 in Combination with Pembrolizumab for Patients with Unresectable or Metastatic Melanoma
Principal Investigator: Puzanov, Igor
(ASTX660-01) Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
Impact of Menthol Delivery Methods on Smoker Sensory Perceptions
Principal Investigator: O'Connor, Richard J
Race and geographic differences in diagnosis with metastatic Prostate cancer and early detection
Principal Investigator: Sumlin, Adam B
TRITON3:A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physicians Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
Principal Investigator: Chatta, Gurkamal S
TISSUE AND DATA ACQUISITION ACTIVITY FOR THE STUDY OF GYNECOLOGIC DISEASE
Principal Investigator: Odunsi, Adekunle O
A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC).
Principal Investigator: Boland, Patrick M
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)
Principal Investigator: Levine, Ellis G
(S1605) Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Principal Investigator: Li, Qiang J
105SAR301, A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS);
Principal Investigator: Grand'Maison, Anne C
NRG-BR005: A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving...
Principal Investigator: Levine, Ellis G
2125-204, A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma
Principal Investigator: Puzanov, Igor
DFCI ALL Consortium 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Principal Investigator: Kelly, Kara M
A Phase 1/2 dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies
Principal Investigator: Odunsi, Adekunle O
AHOD1721, Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin(N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 +classic Hodgkin lymphoma (cHL) after failure of first-line...
Principal Investigator: Kelly, Kara M
Life On The Go 2: Evaluating the Effect of Physical Activity of Patients with Recurrent Ovarian Cancer Using State of the Art Activity Tracking Device
Principal Investigator: Zsiros, Emese
SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms
Principal Investigator: Wang, Eunice S
An open-label, non-randomized, multicenter Phase I study to determine the maximum tolerated and/or recommended Phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY 1436032 and to characterize its safety, tolerability, pharmacokinetics,...
Principal Investigator: Wang, Eunice S
(NCI 9930) A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
Implementing a Low Glycemic Diet in Children and Adolescents Undergoing Treatment for Acute Lymphoblastic Leukemia
Principal Investigator: Kelly, Kara M
(S1609) DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Principal Investigator: Puzanov, Igor
A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation with Post Transplant Cyclophosphamide as Graft versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation
Principal Investigator: Ho, Christine M
Talking Pictures: An exploratory study of meaning-based social media intervention for Adolescent and Young Adult cancer patients
Principal Investigator: Pailler, Megan E
Art Heals
Principal Investigator: Guru, Khurshid
A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Principal Investigator: Iyer, Renuka V
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Principal Investigator: Mohler, James L
(NRG-GU002) Phase II-III Trial Of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or without Adjuvant Docetaxel
Principal Investigator: Chatta, Gurkamal S
Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab or Ipilimumab in Advanced Solid Tumors
Principal Investigator: Puzanov, Igor
Exercise to Improve Health and Quality-of-life in Breast Cancer Survivors
Principal Investigator: O'Connor, Tracey L
YO39523 / GOG-3015: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR...
Principal Investigator: Lele, Shashikant B
A Phase 1b Study of Intratumoral IMO 2125 in Patients with Refractory Solid Tumors (2125-RST-101)
Principal Investigator: Puzanov, Igor
(RTOG 1119) Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis From HER2-Positive Breast Cancer - A Collaboartive Study of NRG Oncology and KROG
Principal Investigator: Prasad, Dheerendra
Direct oral anticoagulants (DOACs) versus LMWH +/- warfarin for VTE in cancer: A randomized effectiveness trial (CANVAS trial)
Principal Investigator: Levine, Ellis G
BMT CTN 1502 Optimizing Haploidentical Aplastic Anemia Transplantation (CHAMP)
Principal Investigator: Bambach, Barbara J
A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
Principal Investigator: Chatta, Gurkamal S
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)
Principal Investigator: George, Saby
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers
Principal Investigator: George, Saby
A Multicenter Pivotal Phase 3 study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects with Active, Relapsed, or Refractory Acute Myeloid Leukemia
Principal Investigator: Chen, George L
An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Principal Investigator: Torka, Pallawi
(CCT-PNK-007-MM-001) A phase 1, multicenter, open-label, safety study of human cord blood derived, culture-expanded, natural killer cell (PNK-007) infusion with or without subcutaneous recombinant human IL-2 (rhIL-2) following autologous stem cell...
Principal Investigator: Ho, Christine M
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Principal Investigator: Wang, Eunice S
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
Principal Investigator: Levine, Ellis G
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
Principal Investigator: Levine, Ellis G
A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion- Positive Tumors (LOXO-TRK-15002).
Principal Investigator: Grand'Maison, Anne C
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Principal Investigator: Chatta, Gurkamal S
INCB 18424-269 (COG AALL1521) A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia
Principal Investigator: Twist, Clare J
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
Principal Investigator: Zsiros, Emese
MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification
Principal Investigator: Levine, Ellis G
A multicenter open-label treatment protocol of gilteritinib (ASP2215) in patients with FMS-like tyrosine kinase 3 (FLT3) mutated relapsed or refractory acute myeloid leukemia (AML) or FLT3 mutated AML in complete remission (CR) with minimal residual...
Principal Investigator: Wang, Eunice S
A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not...
Principal Investigator: Wang, Eunice S
MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
Principal Investigator: Levine, Ellis G
(EAQ152): COMET - Communication and Education in Tumor Profiling:A Randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential...
Principal Investigator: Levine, Ellis G
(S1512) A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)
Principal Investigator: Ernstoff, Marc S
A PHASE 1 STUDY OF ES414 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Principal Investigator: Chatta, Gurkamal S
S1418/BR006) A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 [Pembrolizumab] as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After...
Principal Investigator: Levine, Ellis G
( SCRX001-006) An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Principal Investigator: Dy, Grace K
Vigilant Observation of Gliadel Wafer Implant (VIGILANT) Registry: A multicenter, observational registry to collect information on the safety and effectiveness of Gliadel Wafer (Carmustine Implant) used in usual medical practice
Principal Investigator: Fabiano, Andrew J
An Open Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody Therapeutic, CX-072, as Monotherapy and in Combination with Yervoy® (Ipilimumab) or with Zelboraf® (Vemurafenib) in Subjects with Advanced or Recurrent Solid Tumors or...
Principal Investigator: Opyrchal, Mateusz
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)
Principal Investigator: Dy, Grace K
Study 16-214-02 (Combination): A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214, and Nivolumab, and Ipilimumab in Patients with Select Locally Advanced or Metastic Solid Tumor Malignancies
Principal Investigator: Puzanov, Igor
A phase 1/2 Study of in situ vaccination with tremelimumab and IV durvalumab plus the Toll-like receptor agonist PolyICLC in Subjects with Advanced, Measurable, Biopsy-accessible Cancers
Principal Investigator: Opyrchal, Mateusz
(A011502): A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Principal Investigator: Levine, Ellis G
(COG ANHL12P1) A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC# 749005, Commerically Labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND# 117117
Principal Investigator: Barth, Matthew J
Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naïve prostate cancer that retains RB expression
Principal Investigator: Chatta, Gurkamal S
(COG AAML1531) Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Principal Investigator: Twist, Clare J
A multinational, open-label, dose escalation Phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types
Principal Investigator: Odunsi, Adekunle O
A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects with Previously Treated Hematological Cancers
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents
Principal Investigator: Griffiths, Elizabeth A
S1416, Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer with or Without Metastases
Principal Investigator: Levine, Ellis G
A011401; Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Principal Investigator: O'Connor, Tracey L
A221208; Randomized Phase II Study: Corticosteroids + Bevacizumab VS. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Principal Investigator: Prasad, Dheerendra
(CITN-12) Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Principal Investigator: Ernstoff, Marc S
A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination with Decitabine in Patients with Recurrent or Treatment Refractory Ovarian Cancer
Principal Investigator: Odunsi, Adekunle O
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
Principal Investigator: Levine, Ellis G
A Phase I/II Study of the EGF Vaccine CIMAvax in Combination with the Anti-PD1 Nivolumab in Patients with Previously Treated Advanced NSCLC
Principal Investigator: Dy, Grace K
Double-arm, Randomized Study of Botulinum Toxin Injection as a Pyloric Drainage Procedure for Minimally Invasive Esophagectomy (Phase II)
Principal Investigator: Kukar, Moshim
A Phase I Evaluation of Olaparib in combination with Durvalumab and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients who Carry a...
Principal Investigator: Odunsi, Adekunle O
A Phase I/II Open-Label Study of Nimotuzumab in Combination with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer
Principal Investigator: Dy, Grace K
(EA5142) Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Principal Investigator: Dy, Grace K
A Phase 1, Multi-Center, Open-Label Study of IMGN779 Administered Intravenously in Adult Patients with Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia
Principal Investigator: Wang, Eunice S
National Witness Project Pilot
Principal Investigator: Erwin, Deborah O
(A-US-52030-328) A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Auto/Gel Depot 120 mg Plus BSC Vs. Placebo Plus BSC for Tumor Control in Subjects with Well Differentiated, Metastatic And...
Principal Investigator: Chen, Hongbin
(COG ALTE1621) Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
Principal Investigator: Rokitka, Denise A
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
Principal Investigator: Wang, Eunice S
(EAY 131-V MATCH): Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
Principal Investigator: Levine, Ellis G
(EAY 131-T MATCH): GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
Principal Investigator: Levine, Ellis G
EAY 131-S2 MATCH): Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations
Principal Investigator: Levine, Ellis G
(EAY 131-E MATCH): AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
Principal Investigator: Levine, Ellis G
(EAY 131-G MATCH): Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)
Principal Investigator: Levine, Ellis G
(EAY 131-F MATCH): Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations
Principal Investigator: Levine, Ellis G
(EAY 131-A MATCH): Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Principal Investigator: Levine, Ellis G
Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
(EAY 131 Master Protocol) Molecular Analysis for Therapy Choice (MATCH)
Principal Investigator: Levine, Ellis G
Phase 0 Trial of Presurgical Cholesterol-lowering on Prostate Cancer Cell Growth
Principal Investigator: Mohler, James L
(BMT CTN Protocol 1401) Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccinations with Dendritic Cell/Myeloma Fusions
Principal Investigator: Torka, Pallawi
Phase IB/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Polatuzumab Vedotin and Venetoclax in Patients with Relapsed or Refractory Follicular Lymphoma and Rituximab in combination with polatuzumab vedotin and...
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer
Principal Investigator: George, Saby
A Phase II Evaluation of Pembrolizumab in Combination with IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal Investigator: Zsiros, Emese
A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Principal Investigator: Lee, Kelvin
(EA1131) A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Principal Investigator: Levine, Ellis G
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)-containing Regimens versus nab-Paclitaxel plus Gemcitabine in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Principal Investigator: Boland, Patrick M
(COG APEC14B1) The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Principal Investigator: Twist, Clare J
A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer
Principal Investigator: Boland, Patrick M
(BMT CTN 1302) Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
Principal Investigator: McCarthy, Philip L
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor...
Principal Investigator: Levine, Ellis G
(12-100) Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) or Photon (IMRT) with Simutaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas
Principal Investigator: Kane, John M
(A031102) A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Pacilitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide ...
Principal Investigator: Levine, Ellis G
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Principal Investigator: Levine, Ellis G
A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Activity of Oraxol in Subjects with Advanced Malignancies
Principal Investigator: Opyrchal, Mateusz
(ACCL1333/CV185-155) A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly...
Principal Investigator: Bambach, Barbara J
(COG AAML1331) A Phase III Study For Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Principal Investigator: Twist, Clare J
A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient...
Principal Investigator: Opyrchal, Mateusz
(COG AALL1331) Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC# 765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Principal Investigator: Twist, Clare J
A Phase II, Multicenter, Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (wt), Advanced Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Chen, Hongbin
(COG ANBL1232) Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
Principal Investigator: Higman, Meghan
(COG AHOD1331) A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Principal Investigator: Higman, Meghan
SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Principal Investigator: Wang, Eunice S
(S1400) A Biomarker-Driven Master Protocol for Previously treated Squamous Cell Lung Cancer (Lung-Map)
Principal Investigator: Chen, Hongbin
Phase II Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis against Radiation Pneumonitis in Patients with Unresectable NSCLC Undergoing Chemoradiation Therapy
Principal Investigator: Dy, Grace K
(E4512 )A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Principal Investigator: Chen, Hongbin
(A081105) Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Dy, Grace K
(A151216) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Principal Investigator: Dy, Grace K
(NRG/COG ARST1321) Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
Principal Investigator: Rokitka, Denise A
(BMT CTN 1102) A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic...
Principal Investigator: McCarthy, Philip L
(E2112) A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
Principal Investigator: Levine, Ellis G
A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients with Advanced Malignancies
Principal Investigator: Odunsi, Adekunle O
(E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Principal Investigator: Wang, Eunice S
A Dose-Regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects with Advanced Malignancies
Principal Investigator: Boland, Patrick M
A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination with Gemcitabine-Based Chemotherapy in Patients with Advanced Solid Tumors
Principal Investigator: Iyer, Renuka V
A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given with Adjuvant Poly-ICLC in Combination with INCB024360 for Patients in Remission with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY...
Principal Investigator: Odunsi, Adekunle O
(A011202) A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 NI) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Principal Investigator: Levine, Ellis G
(Alliance A011106) ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Principal Investigator: Levine, Ellis G
(COG ALTE11C2) Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy
Principal Investigator: Rokitka, Denise A
Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults with CD20+ Mature B-Cell Lymphoma
Principal Investigator: Barth, Matthew J
Phase I/II Study of Carfilzomib plus Rituximab plus Ifosfamide plus Carboplatin plus Etoposide (C-R-ICE) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
N1048 PROSPECT**) A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiaiton Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with...
Principal Investigator: Nurkin, Steven J
(1137-101) A Phase I Trial of CBL0137 in Patients with Advanced Solid Neoplasms
Principal Investigator: Iyer, Renuka V
Impact of Carbonyl Reductase 3 Genotype Status on Echocardiographic Measurements of Cardiomyopathy in Breast Cancer Patients Treated with Anthracyclines
Principal Investigator: O'Connor, Tracey L
A Phase I/ II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients
Principal Investigator: George, Saby
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Principal Investigator: Griffiths, Elizabeth A
COG AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk BLymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Principal Investigator: Twist, Clare J
(CIBMTR 10-CBA) A Multicenter Access and Distribution Protocol for Unlicensed Cryopreseved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Principal Investigator: McCarthy, Philip L
Examining Quality of Life Among Long-Term Survivors of Childhood Cancer
Principal Investigator: Rokitka, Denise A
Mediators of inflammation and injury in patients receiving cancer therapy or allogeneic hematopoietic stem cell transplantation
Principal Investigator: Segal, Brahm
(COG ACNS0831) Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years
Principal Investigator: Twist, Clare J
Evaluation and Quality Assurance of the New York State Smokers' Quitline
Principal Investigator: Hyland, Andrew J
Randomized Placebo-Controlled, Double-Blind Study Of Cholecalciferol Replacement in Patients on Expectant Management for Localized Prostate Cancer
Principal Investigator: Mohler, James L
Leukocyte Apheresis for Research
Principal Investigator: Odunsi, Adekunle O
Evaluation of Smoker Reactions to Novel Tobacco Products
Principal Investigator: Bansal Travers, Maansi
Lung Bronchoscopy Research Samples & Database
Principal Investigator: Hennon, Mark W
Collection of Blood from Healthy Donors and Patients with Non-Hodgkin's Lymphoma and Leukemia to Study the Immunological Activity of Peripheral Blood Mononuclear Cells (PBMC) and Human Serum
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
(COG ALTE03N1) Key Adverse Events After Childhood Cancer
Principal Investigator: Rokitka, Denise A
(COG ALTE05N1) Umbrella Long-Term Follow-Up Protocol
Principal Investigator: Rokitka, Denise A
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors (NMDP IRB 1996-005; IRB-1999-0021)
Principal Investigator: McCarthy, Philip L
Novel Risk Factors and Potential Early Detection Markers for Ovarian Cancer
Principal Investigator: Moysich, Kirsten B